What is Cell Science Systems?
Operating as a sophisticated clinical laboratory, Cell Science Systems specializes in the intersection of immunology, cell biology, and molecular diagnostics. The organization is widely recognized for its development of the Alcat Test, a pioneering diagnostic tool designed to identify food and chemical sensitivities. By maintaining a CLIA-certified laboratory and adhering to rigorous FDA-inspected cGMP and ISO EN13485 standards, the company bridges the gap between high-level medical research and actionable patient care. Its operational footprint, which includes a wholly owned European subsidiary, positions it as a key player in the global diagnostics market, facilitating the transition toward data-driven, personalized treatment protocols for complex chronic conditions.
How much funding has Cell Science Systems raised?
Cell Science Systems has raised a total of $813K across 2 funding rounds:
Debt
$350K
Debt
$463K
Debt (2020): $350K with participation from PPP
Debt (2021): $463K led by PPP
Key Investors in Cell Science Systems
PPP
Public-Private Partnership
What's next for Cell Science Systems?
With the recent influx of capital, Cell Science Systems is poised to accelerate its research and development initiatives, particularly in the refinement of its molecular diagnostic suite. The strategic focus will likely shift toward enhancing laboratory throughput and expanding the clinical utility of its existing diagnostic portfolio. As the healthcare sector increasingly prioritizes preventative and personalized interventions, the company is well-positioned to leverage its regulatory compliance and technical expertise to capture additional market share. Future growth will likely be driven by the integration of advanced analytical technologies and the scaling of its international operations to meet the rising demand for specialized immunological testing.
See full Cell Science Systems company page
